ALGEN genOway Société anonyme
genOway Société anonyme, a biotechnology company, engages in the development and commercialization of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines, such as constitutive and inducible KO, point mutation KI, reporter KI, quick KI, and KI cell lines. The company also offers humanized immune checkpoint mouse models; immunodeficient and reconstituted mouse and rat strains models; humanized immune target models; other mouse and rat catalog models; and cell lines. It serves pharmaceutical and life science companies, and academic institutes. The company was incorporated in 1999 and is based in Lyon, France.…
Industry Peers
BiotechnologyKey Statistics
About genOway (EPA: ALGEN)
›
genOway (EPA: ALGEN) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 1.880 EUR on 19 November 2026, down 26.0% over 52 weeks. Its 52-week range is 1.810 EUR to 2.880 EUR: the price is 34.7% below the high and 3.9% above the low.
Its market capitalisation is 24.06M EUR.
genOway reports return on equity of 3.7%, an operating margin of -5.7% and revenue down 12.4% year over year.
Its debt exceeds its cash by 11.92M EUR, a debt-to-equity ratio of 0.55. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.